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Abstract.  GMP-140  is a rapidly inducible receptor for 
neutrophils and monocytes expressed on activated 
platelets and endothelial cells. It is a member of the 
selectin family of lectin-like cell surface molecules 
that mediate leukocyte adhesion. We used a radio- 
ligand binding assay to characterize the interaction of 
purified GMP-140  with human neutrophils. Unstimu- 
lated neutrophils rapidly bound [12~I]GMP-140 at 4°C, 
reaching equilibrium in 10-15  min. Binding was Ca  2÷ 
dependent, reversible, and saturable at 3-6 nM free 
GMP-140  with half-maximal binding at =1.5 nM. 
Receptor density and apparent affinity were not altered 
when neutrophils were stimulated with 4/~-phorbol  12- 
myristate 13-acetate. Treatment of neutrophils with 
proteases abolished specific binding of [125I]GMP-140. 
Binding was also diminished when neutrophils were 
treated with neuraminidase from Vibrio  cholerae, 
which cleaves ix2-3-, a2-6-,  and ot2-8-1inked sialic 
acids,  or from Newcastle disease virus, which cleaves 
only a2-3- and tx2-8-1inked sialic acids.  Binding was 
not inhibited by an mAb to the abundant myeloid 
oligosaccharide, Le  x (CD15),  or by the neoglyco- 
proteins Lex-BSA and sialyl-Le~-BSA. We conclude 
that neutrophils constitutively express a glycoprotein 
receptor for GMP-140, which contains sialic acid 
residues that are essential for function. These findings 
support the concept that GMP-140 interacts with leu- 
kocytes by a lectin-like mechanism. 
HESIVE interactions of leukocytes with other blood 
cells  or vascular endothelium are  fundamental to 
many  aspects  of  immune  and  inflammatory  re- 
sponses (15, 25, 60, 61).  The selectins are a new family of 
structurally related molecules that participate in these events 
(5, 20, 28, 46). The three known selectins are (a) endothelial 
leukocyte  adhesion  molecule-1  (ELAM-1), 1  a  cytokine- 
inducible endothelial cell receptor for neutrophils (4) and 
monocytes (17); (b) the peripheral lymph node lymphocyte 
homing receptor (murine Mel 14 antigen or human Leu 8 an- 
tigen/LAM-1), a molecule also expressed on neutrophils and 
monocytes which may participate in leukocyte extravasation 
at sites of inflammation (22, 24); and (c) granule membrane 
protein-140 (GMP-140,  PADGEM protein, CD62), a recep- 
tor for neutrophils and monocytes that is rapidly mobilized 
from secretory storage granules to the surface of activated 
platelets (14, 27) and endothelium (13, 16, 32). Each selectin 
contains  an  NH2-terminal  domain  homologous  to  Ca  2+- 
dependent lectins (9), followed by an EGF-like domain, a se- 
ries of consensus repeats similar to those in complement- 
regulatory proteins, a transmembrane domain, and a short 
cytoplasmic tail (5-7, 20, 28,  46, 55). 
1.  Abbreviations  used in  this paper:  DFE  diisopropylfluorophosphate; 
ELAM-1, endothelial leukocyte  adhesion molecule 1; GMP-140, granule 
membrane protein-140; HSA; human serum albumin; PPME, phospho- 
mannan monoester  core from  Hansenula  hostii. 
The binding properties of selectins have not been well 
studied nor have any of their receptors been identified. How- 
ever, the conservation of domains related to Ca2+-dependent 
lectins and the common requirement for Ca  2÷ to  support 
leukocyte adhesion (13, 14, 17, 27, 64) suggest that the selec- 
tins may bind to oligosaccharide targets. This hypothesis is 
strengthened by observations that lymphocyte adhesion to 
peripheral  lymph node HEVs mediated by the peripheral 
lymph node homing receptor is inhibited by certain carbohy- 
drate-rich structures such as fucoidin and the mannose-6- 
phosphate-rich polysaccharide PPME (64) and by pretreat- 
ment of HEVs with neuraminidase (40). 
In this study, we used a radioligand binding assay to exam- 
ine the interaction of  purified GMP-140 with blood cells. The 
time course, reversibility, and saturability of GMP-140 bind- 
ing to human neutrophils were studied. We also examined 
whether binding  was  affected by  neutrophil  activation or 
fixation,  by  soluble carbohydrates,  or by pretreatment of 
neutrophils with proteases or glycosidases. 
Materials and Methods 
Materials 
Leupeptin, antipain, aprotinin,  benzamidine,  4/3-phorbol 12-myristate 13- 
acetate, 0.4% trypan blue stain, Histopaque, Sephadex G-75 and phos- 
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Louis, MO). N-Tosyl-L-phenylalanine chloromethyl ketone-treated trypsin 
(TPCK-trypsin; 222 U/rag) and porcine pancreatic elastase (Z8 U/mg) were 
purchased from Worthington Biochemical Corp. (Freehold, NJ). Endo-~- 
galactosidase from Escherichia freundii was a gift from Miehiko Fukuda 
(La Jolla Cancer Research Foundation, La Joila, CA). Endo-B-galactosi- 
dase from Bacteroides fragilis, neuraminidase from Vibrio cholerae,  and 
2,3-dehydro 2,6-anhydro N-acetyl neuraminic acid (Neu2en5Ac) were ob- 
tained from Boehringer-Mannheim Biochemicals (Indianapolis, IN). New- 
castle disease virus (NDV) was isolated as previously described (37). En- 
zymobeads and  Affignl-10  were purchased  from  Bio-Rad  Laboratories 
(Richmond, CA), carrier-freo Nat2~I from Amersham Corp.  (Arlington 
Heights, IL), and HBSS from Gibco Laboratories (Grand Island, NY). Di- 
isopropylfluorophosphate  (DFP) and Triton X-100 (Protein Grade) were ob- 
tained from Calbiochem-Behring Corp. (La Jolla, CA). Human serum albu- 
min (HSA) was from Cutter Biologicals (Elkhart, IN). The Micro BCA 
protein assay kit and Lnbroi-PX (Surfact Amps PX) were purchased from 
Pierce Chemical Co. (Rockford, IL). PPME, the phosphomannan mono- 
ester core from Hansenuta hostii (48), was a gift from Steven Rosen (Uni- 
versity of California, San Francisco). FITC-anti-Leu 8, FITC-anti-Leu-M1 
(Le  x,  CDI5)  and PE-anti-Leu  15  (CDllb/CDI8)  mAbs were purchased 
from Becton-Dickinson Co. (Mountain View, CA). FITC-conjugated goat 
anti-mouse  IgG/IgM  F(ab')  2  was  purchased  from  Caltag  Laboratories 
(South  San Francisco, CA).  The murine anti-Lewis  x (Le  x,  CD15)  IgM 
mAb, 82H5 (19), was isolated by affinity chromatography on a silica column 
to which Le  x (Gal~/1-4(Fuccd-3)GIcNAc)  was immobilized (0.5 ~mol oligo- 
saccharide/g silica: Synsorb-X). Le  x and sialyi-Le  x were synthesized (36) 
and coupled to BSA (=10 oligosaccharides/BSA  molecule) as previously de- 
scribed (29). The anti-Le  ~ monoclonal antibody, sialyl-Le~-BSA, and Le  x- 
BSA were gifts from Murray Ratcliffe (Chembiomed Ltd., Edmonton, Al- 
berta). 
Neutrophil Isolation 
Human neutrophils, isolated as previously described (14), were suspended 
to 4  ×  106/ml in Ca2+/Mg2+-free HBSS, supplemented with 1 mg/ml HSA 
and  1 mM Ca  2+ (HBSS/HSA/Ca), and kept at 4°C until use. Neutrophil 
suspensions were routinely >95 % pure by examination of Wright-Giemsa- 
stained smears and >95% viable by trypan blue exclusion. For certain ex- 
periments, neutrophils were incubated with HBSS/HSA/Ca containing ei- 
ther 100 nM PMA or diluent at 22°C for 30 rain. Quiescent and activated 
neutrophils were either washed once with HBSS/HSA/Ca and chilled on an 
ice bath, or fixed with one-eighth volume of 8 % paraformaldehyde for 30 min 
at 22°C, followed by addition of one-eighth volume of  0.5 M glycine/0.25 M 
Tris, pH Z5. Fixed ceils were washed three times with HBSS/HSA/Ca and 
chilled in an ice bath before use. 
Erythrocyte Isolation 
9 mi of whole blood anticoagulated with 1 ml ACD Solution A  (Becton- 
Dickinson Co., Rutherford, NI) was centrifuged for 10 rain at  1300 g at 
22°C. After removing the plasma and buffy coat, 1 ml of packed erythro- 
cytes was diluted with 10 ml of HBSS/HSA/Ca, and centrifuged for 5 rain 
at 1,100 g. This wash step was repeated three times. The erythrocyte suspen- 
sions contained <0.1%  leukocytes and platelets as assessed by phase con- 
trast microscopy. 
Lymphocyte and Monocyte Isolation 
Whole  blood  anticoagulated  with  5  mM  EDTA  was  diluted  1:1  with 
Ca2+/Mg2+-free  HBSS  supplemented with  1  mg/ml  HSA  and  5  mM 
EDTA. 25 ml of diluted blood were layered on 10 ml of Histopaque and 
centrifuged at 400 g at 22°C for 40 min. The mononuclear cell layer was 
collected, diluted with 10 volumes of Ca2+/Mg2+-free HBSS supplemented 
with I mg/ml human serum albumin and 1 mM EDTA (HBSS/HSA/EDTA), 
and centrifuged at 400 g for 5 rain. The cell pellet was resuspended with 
40 ml of HBSS/HSA/EDTA and centrifuged at 100 g for 10 min at 22°C. 
After removing the platelet-rich supernatant, the mononuclear cell pellet 
was resuspended with 5 ml of HBSS/HSA/EDTA. Lymphocytes and mono- 
cytes were separated by countercurrent centrifugal elutriation using a cen- 
trifuge (model JA-21; Beckman Instruments, Fullerton, CA) equipped with 
an Beckman JE-6 elutriation rotor using minor modifications of previously 
described methods (63). Before use, the elutriation system was flushed with 
500 ml sterile water followed by 500 ml 6% hydrogen peroxide (Mallinck- 
rodt, Pads, KY), 1,000 ml pyrogen-free sterile water, USP (Abbott Labora- 
tories, North Chicago, IL), and 500 ml HBSS/HSA/EDTA. After elutria- 
tion was completed, the fractions were centrifuged at 400 g for 10 min at 
40C and each pellet was resnspended in 0.5 ml HBSSIHSAIEDTA. Before 
use, the fractions were washed with HBSS/HSA/Ca. The cellular composi- 
tions  of the pooled lymphocyte and  monocyte fractions were assessed 
by differential counting of Wright-Giemsa-stained smears.  Lymphocyte 
fractions were >99% pure and monocyte fractions were 60-95 % pure. The 
contaminating cells in the monocyte fractions were predominantly lympho- 
cytes. In three separate experiments, [125I]GMP-140 binding to pure lym- 
phocytes and  to  monocyte-enriched populations was determined as de- 
scribed below.  As these studies revealed minimal binding of GMP-140 to 
lymphocytes, GMP-140 binding per 10  ~ monocytes was calculated by sub- 
tracting the low level binding due to contaminating lymphocytes from total 
GMP-140 bound to the monocyte-enriched fraction. 
Platelet Isolation and Activation 
Quiescent human platelets were isolated as previously described (14). Plate- 
lets (5  x  10S/ml) in HBSS/HSA/Ca were incubated with 1 U/ml bovine 
c~-thrombin or buffer for 10 rain at 22°C without stirring, in the presence of 
1 mM Arg-Gly-Asp-Ser (RGDS).  Aliquots (250 #1) were then added directly 
to mixtures containing 2.3 nM [125I]GMP-140 with or without 100-fold ex- 
cess unlabeled GMP-140 as described below.  Control experiments showed 
that 1 mM RGDS had no effect on binding of GMP-140  to neutrophils. 
GMP-140 Purification 
Platelet GMP-140 was purified from outdated  human platelets obtained 
from the Oklahoma Blood Institute and the American Red Cross of Tulsa 
using a modification of a previously reported procedure (33). Briefly, plate- 
lets were extensively washed with 0.1 M NaCI, 20 mM Tris, pH 7.5, 5 mM 
benzamidine, 5 mM EDTA, and frozen at -70oC until use. Frozen platelets 
(100 units) were thawed, and leupeptin (100/~M) and DFP (1 raM) were 
added. The platelet suspension was freeze-thawed three times in a dry ice- 
acetone bath and then homogenized. After centrifuging the homogenate for 
45 min at 4°C at 46000 g, the membrane pellet was solubilized in 200 mi 
of 0.1 M  NaCI, 20 mM Tris, pH 7.5, 5 mM EDTA, 5 mM benzamidine, 
100/~M leupeptin, 2% Triton X-100. This mixture was stirred for 30 min 
at 4°C and then centrifuged for 45 min at 46000 g. The supernatant was 
made 0.5 M  in NaCt and passed through a 2.5  x  10 cm Sephadex Go75 
column hooked in series to a 1.5  x  20 cm Affigel-10 column to which the 
anti-GMP-140 mAb S12 (33) was coupled at a density of 5 nag of antibody 
per ml of resin. Both columns were equilibrated at room temperature with 
0.5 M NaCI, 20 mM Tris, pH 7.5, 0.02%  sodium azide. The S12-Affigel-10 
column was extensively washed with equilibration buffer containing 0.01% 
Lubrol PX at 4°C and bound protein was eluted with 80% ethylene glycol, 
1 mM  MES,  pH 6.0,  0.02%  sodium azide, 0.01% Lubrol PX.  Protein- 
containing fractions were pooled, dialyzed against 0.1  M  NaC1,  20 mM 
Tris, pH 7.5,  0.01% Lubrol PX, and applied to a 5  x  50 mm Mono Q 
column (Pharmacia Fine Chemicals, Piscataway,  NJ) equilibrated in the 
same buffer. The column was washed extensively and then step eluted with 
2 M NaCI, 20 mM Tris, pH 7.5. 0.01% Lubrol PX. The protein-containing 
fractions were pooled and dialyzed against 0.1 M NaCI, 20 mM Tris, pH 
7.5, 0.01% Lubrol PX, and stored at 4°C. This material was homogeneous 
as judged by SDS-PAGE (26)  and NH2-terminal amino acid sequencing. 
Protein lodination 
GMP-140 was iodinated by the lactoperoxidase method using Enzymobeads 
according to the manufacturer's instructions. 40/~g of GMP-140 was labeled 
with 0.1-1.0 mCi carrier-free Na[125I] and free [125I] was removed by gel 
filtration through a prepacked Sephadex G-25 column (PD-10,  Pharmacia 
Fine Chemicals) equilibrated in 0.1 M NaCl, 20 mM Tris, pH 7.5, 0.01% 
Lubrol PX. The void volume fractions were pooled and the protein concen- 
tration was determined with the Micro BCA protein assay reagent using 
BSA as a standard. The labeled protein was made 0.1% gelatin and stored 
at 4°C until use. The specific activity of the radiolabeled protein ranged 
from 0.81-15.2/~Ci/#g protein and was routinely >95% TCA precipitable. 
Radioligand Binding Assay 
Binding assays were performed by combining 10/~1 [125I]GMP-140 and 250 
#l HBSS/HSA/Ca containing varying concentrations of  uniabeled GMP-140 
in a 1.5-ml siliconized polypropylene microfuge tube. The assay was initi- 
ated by adding 250/zl of neutrophils suspended in HBSS/HSA/Ca at 4  x 
106/ml.  The tubes were incubated at 4°C on an oscillating platform. At 
various times, the tubes were vortexed briefly,  and 450 #1 of the mixture 
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NJ) in another 1.5-ml microfuge tube. To separate free from cell-bound ra- 
diolabeled GMP-140,  the tubes were centrifuged for 5 min at 16,000 g  in 
an Eppendorf  model 5415 centrifuge equipped with a fixed angle rotor. The 
tips were amputated into 12  x  75 mm test tubes and the radioactivity in 
each cell pellet was measured in a gamma counter (series 500;  Iso-Data 
Inc., Rolling Meadows, IL). All components were chilled on an ice bath 
before  the  assay  and  unless  indicated,  all  assays  were  performed  in 
duplicate. 
For studies of time course, antibody inhibition, enzyme susceptibility, 
and reversibility of binding, [t2SI]GMP-140 was present at a final concen- 
tration of 0.1-0.3  nM, whereas for experiments measuring maximal GMP- 
140 binding to various blood cells, [125I]GMP-140 was present at 2-3 nM. 
In these experiments, specific binding was calculated as total binding minus 
nonspecific binding, defined as [125I]GMP-140 bound in the presence of 
100-fold  molar excess unlabeled GMP-140.  Nonspecific binding ranged 
from 10--30%  of total binding. 
Saturability of [1251]GMP-140 binding to neutrophils was analyzed by 
incubating cells with 0.1-0.2 nM [t251]GMP-140 in the presence of increas- 
ing concentrations of unlabeled GMP-140 (0-6.3 nM). Disintegrations per 
minute bound in the presence of  50 nM unlabeled GMP-140 (>250-fold mo- 
lar excess over added [t25I]GMP-140) was defined as non-specific binding. 
Nonspecific binding, which was assumed to be constant, was subtracted 
from total binding at each input of unlabeled GMP-140.  GMP-140 bound 
(femtomoles) was then calculated by dividing specific binding (disintegra- 
tions per minute) by  specific activity (disintegrations per minute/femto- 
moles),  which decreases as a  function of increasing input of unlabeled 
GMP-140. 
Elution of  Bound [uS  I]GMP-140 
Neutrophils (106) were incubated with 2.6 nM  [125I]GMP-140 in HBSS/ 
HSA/Ca as described above for 30 min, then rapidly washed three times 
with cold HBSS/HSA/Ca.  The washed neutrophils were resuspended in 
250  /~1  of HBSS/HSA/Ca  containing 260  nM  unlabeled GMP-140  and 
incubated an additional  10  rain at 4°C.  After centrifugation, the radio- 
activity was measured in both the supernatant and cell pellet; =62% of the 
total  [125I]GMP-140 was recovered in the supernatant. An aliquot of the 
supernatant and an equimolar quantity of [125I]GMP-140 from the same io- 
dination were electrophoresed on a 7.5%  SDS polyacrylamide gel under 
reducing conditions and analyzed by autoradiography using an AMBIS 
radioanalytical imaging system (AMBIS Systems, Inc., San Diego, CA). 
Enzymatic Treatment of Neutrophils 
Nentrophils, suspended in HBSS/10  mM MOPS, pH 7.5 (HBSS/MOPS), 
were treated twice at 22°C for 10 min with 2 mM DFP to inactivate endoge- 
nous serine proteases (1). The cells were then washed with HBSS/MOPS 
and fixed.  Fixed neutrophils (7.5  x  106/ml)  in  HBSS/MOPS,  were in- 
cubated at 37°C with TPCK-trypsin (0.77/~M,  41 U/ml) for 10 min or with 
elastase (40 ~M, 7.8 U/ml) for 30 min. Control cells were incubated under 
identical conditions with the same concentrations of enzyme previously in- 
activated with DFP or buffer alone. After the incubation period, DFP was 
added to 2 mM and the cells were pelleted at 400 g  for 5 rain. The cells 
were resuspended with HBSS/MOPS and DFP was added again to 2 mM. 
After centrifugation at 400 g  for 5 min, the cell pellets were resuspended 
to 4  x  106/ml in HBSS/HSA/Ca and specific binding of [t25I]GMP-140 
was determined. In other experiments, DFP-treated fixed neutrophils (1.6 
×  107/ml) in 0.15 M NaCI, 50 mM acetate, pH 6.0, 10 mg/ml HSA, 9 mM 
CaCI2,  0.05 % sodium azide (digestion buffer) were incubated with neur- 
aminidase, endo-/3-galactosidase,  or buffer for varying time periods at 37°C 
in the presence of  20 tiM leupeptin, 30 tiM antipain, 0.64 mM benzamidine, 
and 100 KIU/ml aprotinin. In some incubations 0.5-20 mM of the neur- 
aminidase  inhibitor  Neu2en5Ac,  dissolved in  digestion buffer,  was  in- 
cluded.  At these concentrations the pH of the reaction mixture was not 
affected by the inhibitor.  After enzyme treatment the cells were washed 
twice with cold HBSS/HSA/Ca and resuspended in HBSS/HSA/Ca to 4  x 
106/ml  before measurement of [125I]GMP-140 binding.  The NDV  neur- 
aminidase used was a suspension of virus particles, each of which contains 
~103 neuraminidase molecules, whereas the V. cholerae  enzyme is in so- 
lution. 
Flow Cytometry 
Unstimulated or PMA-stimulated nentrophils were analyzed by direct im- 
munofluorescence by combining 50/zl of cells (2  x  107/Iill) with FITC- 
anti-Leu 8 (5.5/~g/ml), PE-anti-Leu 15 (22/zg/ml), FITC-anti-Leu-M1 (4.2 
#g/ml), or buffer in the presence or absence of either Lex-BSA or sialyl- 
Lex-BSA (106 #g/ml), and incubated in an ice bath for 30 min. Unstimu- 
lated neutrophils were also analyzed by indirect immunofluorescence in 
which 50 #1 of nentrophils (2  x  107/ml) were incubated with 4.2/~g/ml of 
the anti-Le  x mAb 82H5  in the presence or absence of either Lex-BSA or 
sialyl-LeX-BSA  (106 #g/ml) for 20 min at 4°C, then washed with 1.5 ml 
HBSS/HSA/Ca.  The cells were pelleted at 16,000 g for 10 s, resuspended 
with 50 #1 HBSS/HSA/Ca, and then incubated for an additional 20 min at 
4°C with FITC-conjugated goat anti-mouse IgG/IgM F(ab')2 at a final con- 
centration of 11  ttg/ml. Samples were diluted with 1.0 rnl Haerna-Line-2 
buffer (Baker Instruments, Allentown, PA) and immediately analyzed in a 
Becton Dickinson FACScan  ® flow cytometer formatted for two-color analy- 
sis. The light scatter channels were set on linear gains and the fluorescence 
channels were set on logarithmic gains. 5,000 fluorescent particles from 
each sample were analyzed for forward and right angle light scatter and for 
either FITC or PE fluorescence intensities with ungated acquisition. 
Results 
Binding of  GMP-140 to Neutrophils 
To examine the interaction of purified [~25I]GMP-140 with 
blood cells we exploited the observation that GMP-140, al- 
though it is  a  transmembrane protein,  remains soluble in 
buffer containing Lubrol PX at concentrations well below its 
critical micellar concentration (CMC). Analytical sedimen- 
tation velocity analysis of purified GMP-140 in buffers con- 
taining Lubrol PX at or above its CMC (100 #M, 0.0058%) 
indicates that the protein sediments as a homogeneous, mono- 
meric species with a sedimentation coefficient of =4.5 S. At 
detergent concentrations comparable to those used in our 
binding studies (<0.0001%), =50 % of the protein sediments 
as  a  monomer and the remainder is  a  mixture of soluble 
oligomers of limited size (n <  10, S <  10) (Moore, K. L., and 
T.  M.  Laue, unpublished observations). 
Figure  1.  Time  course  of p25I]GMP-140  binding to  neutrophils. 
Unstimulated  neutrophils  (106  cells)  were  incubated  with  [t25I] 
GMP-140 (0.1-0.3 nM) in the presence or absence of 100-fold molar 
excess unlabeled GMP-140  for the indicated time period at 4°C. 
Bound and free [125I]GMP-140 were separated as described in Ma- 
terials and Methods. The arrow indicates the addition of 100-fold 
molar excess unlabeled GMP-140. Specific binding in two indepen- 
dent experiments is displayed. The inset shows an autoradiogram 
of a 7.5 % SDS polyacrylamide gel, run under reducing conditions, 
of [~25I]GMP-140  (lane 1)  and bound  [~25I]GMP-140  eluted from 
neutrophils by 100-fold molar excess unlabeled GMP-140 in a sepa- 
rate experiment as described in Materials and Methods. (lane 2). 
(DF,  dye front.) 
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EGTA on [t251]GMP-140 Binding to Neutrophils 
Final 
Agent added  concentration  % Control (n) 
Antibody 
G1  10 #g/rnl  3  (2) 
G2  10/zg/ml  3  (2) 
G3  10/zg/ml  29 (2) 
S12  10 #g/ml  113 (2) 
W40  10 #g/ml  106 (2) 
EGTA  5  mM  7  (4) 
Neutrophils (l&) were incubated with []2~I]GMP-140 (0,1-0.3 nM) for 1 h at 
4°C in the presence of the agent indicated.  Bound and free [12Sl]GMP-140 were 
separated  as  described  in  Materials  and  Methods.  Specific  binding  of 
[~zSI]GMP-140 is expressed as a percentage of that observed in the absence of 
antibody or EGTA. All assays were performed in duplicate and the result shown 
is the mean of the indicated  number of independent experiments. 
To determine the  time  course of GMP-140  binding  to 
quiescent neutrophils, 106 cells were incubated with 0.1-0.3 
nM [~2SI]GMP-140 in the presence or absence of excess un- 
labeled GMP-140 for varying time periods at 4°C. Specific 
binding  proceeded rapidly,  with  equilibrium reached be- 
tween  10 and  15  min  (Fig.  1).  Binding of [~25I]GMP-140 
was rapidly and completely reversed when 100-fold molar 
excess unlabeled GMP-140 was added at equilibrium (arrow, 
Fig.  1). 
To assess whether GMP-140 bound to the neutrophil sur- 
face undergoes proteolytic processing, neutrophils were in- 
cubated  with  2.6  nM  [~25I]GMP-140. Bound  radiolabeled 
protein was  eluted with  100-fold molar excess unlabeled 
GMP-140 and then analyzed by SDS-PAGE and autoradiog- 
raphy as described in Materials and Methods. The eluted ra- 
diolabeled  protein  comigrated  with  intact  [~25I]GMP-140 
(inset, Fig.  1), indicating that the specific binding observed 
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Figure 2.  Steady-state binding of GMP-140 to neutrophils. Un- 
stimulated and PMA-stimulated neutrophils (106 cells) were in- 
cubated with [~25I]GMP-140 (0.1-0.2 nM) in the presence of in- 
creasing concentrations of unlabeled GMP-140 (0-6.3 nM) for 1 h 
at 4°C. Bound and free [125I]GMP-140  were separated and specific 
binding was determined as described in Materials and Methods. 
Binding data from two paired experiments (circles, squares) are 
shown. Closed and open symbols indicate data for unstimulated 
and PMA-stimulated neutrophils, respectively. 
is not due to a minor contaminant in the GMP-140 prepara- 
tion and that bound GMP-140 is not degraded. 
GMP-140-mediated  adhesion  of neutrophils  to  throm- 
bin-activated platelets  (14,  27)  and  to thrombin-activated 
endothelial cells (G. A. Zimmerman, personal communica- 
tion) requires Ca  2+ and is blocked by some mAbs to GMP- 
140 (G1, G2, and G3) but not by others (S12, W40) (13, 14). 
Table I  indicates that binding of ['25I]GMP-140 to neutro- 
phils was also inhibited by chelation of extracellular Ca  2+. 
Furthermore, GMP-140 binding was blocked by the mAbs 
G1, G2, and G3, but not by S12 or W40. 
The saturability of  GMP-140 binding to unstimulated neu- 
trophils was assessed in competitive binding experiments as 
described in Materials and Methods. Fig. 2 shows the results 
of two representative experiments (closed symbols). Specific 
binding was concentration dependent and saturable at 3-6 
nM free GMP-140 with half-maximal binding occurring at 
=1.5  nM  GMP-140.  At saturation  =35  fmol of GMP-140 
bound  to  106  neutrophils.  Activation of neutrophils  with 
100 nM PMA had no effect on these binding parameters 
(Fig.  2,  open symbols).  In these two paired experiments, 
half-maximal binding occurred at  1.4 and 2.2 nM for un- 
stimulated cells and 0.9 and 2.1 nM for stimulated cells. Due 
to the heterogeneous sedimentation behavior of GMP-140 at 
detergent concentration below the CMC,  an accurate esti- 
mate of the number of binding sites cannot be determined by 
Scatchard analysis.  If only monomeric GMP-140 interacts 
with neutrophils, the maximal binding observed (---35 fmol/ 
106 cells) corresponds to =20,000 sites per cell. If the oligo- 
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Figure  3.  Fluorescence  analysis of  unstimulated  and  PMA- 
stimulated neutrophils. Neutrophils incubated with.either 100 nM 
PMA or diluent for 30 min at 22°C were analyzed for surface ex- 
pression ofLeu 8 antigen (top) and Leu 15 antigen (bottom) by flow 
cytometry using FITC-anti-Leu 8 and PE-anti-Leu 15, respectively. 
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GMP-140  to  various  blood 
ceils.  Human  neutrophils 
(PMN), monocytes (MONO), 
lymphocytes  (LYMPH), and 
erythrocytes (RBC) (llY cells) 
and quiescent (PLT)  or throm- 
bin-activated platelets (*PLT) 
(10  s cells) were incubated with 
[t25I]GMP-140  (2.4  nM)  in 
the  presence  or  absence  of 
100-fold molar excess of unla- 
beled GMP-140 for 1 h at 4°C. 
Bound and free p~I]GMP-140 
were separated as described in 
Materials  and  Methods.  All 
assays were performed in qua- 
druplicate.  Specific binding is expressed as femtomoles GMP-140 
bound/106cells, except for binding to platelets, which is expressed 
as femtomoles GMP-140 bound/1.5  x  107 cells (mean  +  SD). 
mers also bind, the actual number of sites may be consider- 
ably lower. Despite limitations in quantitative interpretation, 
the data demonstrate that neutrophil activation does not alter 
the apparent affinity or number of  binding sites for GMP-140. 
The state of activation of the cells was analyzed by measur- 
ing surface expression of both the Leu 8 antigen and Leu 15 
antigen (CDllb/CDI8) using flow cytometry. Fig.  3  shows 
fluorescence histograms of unstimulated and PMA-stimulated 
neutrophils stained with FITC-anti-Leu 8 (top) and PE-anti- 
Leu  15 (bottom).  These data confirm previous reports that 
cellular activation downregulates surface expression of the 
Leu 8 antigen but upregulates expression of the Leu 15 anti- 
gen (22, 24). The inverse modulation of these two adhesive 
receptors by PMA contrasts with the lack of effect of PMA 
on specific binding of [t2SI]GMP-140 to neutrophils.  To en- 
sure that GMP-140 did not activate neutrophils during the as- 
say period, as assessed by these criteria, unstimulated neu- 
trophils were incubated with GMP-140 (40-50 nM) or buffer 
for 60 min at 4°C, followed by measurement ofLeu 8 antigen 
and  Leu  15  antigen  expression by flow cytometry.  Under 
these conditions GMP-140 had no effect on either Leu 8 or 
Leu 15 antigen expression when compared with sham-treated 
controls (data not shown). 
To determine if the interaction of GMP-140 with neutro- 
phils was affected by fixation, unstimulated and PMA-stim- 
ulated  neutrophils  were  fixed with  1%  paraformaldehyde, 
then incubated for 1 h at 4°C with near saturating concentra- 
tions of [~2q]GMP-140  (2.4-2.6 nM). Fixation did not alter 
the amount of GMP-140 specifically bound to either unstim- 
ulated or stimulated neutrophils when compared with sham- 
treated controls (n  =  3,  data not shown). 
Binding of GMP-140 to Other Blood Cells 
Neutrophils, erythrocytes, lymphocytes, monocytes, or plate- 
lets were incubated with 2.4 nM [~25I]GMP-140 in the pres- 
ence or  absence of excess unlabeled  GMP-140.  GMP-140 
bound specifically to monocytes as well as neutrophils, but 
not  to  erythrocytes or  to  unstimulated  or  thrombin-stim- 
ulated platelets (Fig. 4). Very low levels of binding to unfrac- 
tionated peripheral blood lymphocytes were observed. This 
may represent specific interactions of GMP-140 with a subset 
of lymphocytes or with a  small number of contaminating 
monocytes. 
Effect of  Soluble Carbohydrates on GMP-140 Binding 
Adhesion of lymphocytes to HEVs mediated by the periph- 
eral lymph node homing receptor (Mel 14/Leu 8 antigen) is 
inhibited by the phosphorylated monosaccharides, fructose- 
1-phosphate and mannose-6-phosphate, and by the mannose- 
6-phosphate-rich  polysaccharide,  PPME  (53,  64).  Fig.  5 
demonstrates that the  same concentrations of these sugars 
did not markedly inhibit binding of [t25I]GMP-140  to neu- 
trophils.  In  contrast,  binding  was  almost  completely  in- 
hibited  by  10  mM  mannose-l-phosphate,  which  does  not 
block lymphocyte adhesion to HEV (64). This suggests that 
the carbohydrate structures recognized by GMP-140 and the 
peripheral  lymph node homing receptor are distinct.  The 
actual receptor for GMP-140 is unlikely to be mannose-1- 
phosphate,  because  high  concentrations  of the  sugar are 
required  to  inhibit  [~25I]GMP-140 binding  and  mannose-1- 
phosphate has not been described in N- or O-linked glycans. 
Structural Features of the Neutrophil Receptor 
for GMP-140 
DFP-treated, fixed neutrophils were incubated with various 
enzymes  before  measurement  of  [125I]GMP-140  binding. 
Treatment with trypsin or elastase decreased specific GMP- 
140 binding to 4 and 5 %, respectively, when compared with 
sham-treated cells,  whereas DFP-inactivated enzymes had 
no effect on GMP-140 binding (Fig. 5). These data indicate 
that GMP-140 binds either to a cell surface protein(s) and/or 
to structure(s) associated with a protein. 
DFP-treated fixed neutrophils were also treated with neur- 
aminidase from either V. cholerae, which cleaves a2-3-, c~2- 
6-, and ot2-8-1inked  sialic acids (43), or the Newcastle dis- 
ease virus, which cleaves only a2-3- and tx2-8-1inked  sialic 
acids (38,  43).  After 10-30 min of incubation with 0.1-0.2 
U/ml of V. cholerae or NDV neuraminidase, specific GMP- 
140 binding decreased to 28  +  9  and 52  5=  9%  (mean  + 
SD, n  =  7), respectively, when compared with sham-treated 
controls (Fig. 6). To minimize the possibility that this effect 
Figure 5. Effect of soluble car- 
bohydrates  on  [125I]GMP-140 
binding to neutrophils. Human 
neutrophils (106 cells) were in- 
cubated  with  [t25I]GMP-140 
(0.2-0.3  nM)  and  mannose- 
6-phosphate  (M6P),  man- 
nose-l-phosphate  (  MIP ), 
fructose-6-phosphate  (F6P), 
fructose-l-phosphate  (HP), 
or PPME in the presence  or 
absence of 100-fold molar ex- 
cess  unlabeled  GMP-140 for 
1 h  at  4°C.  Phosphorytated 
monosaccharides  were  pres- 
ent at 10 raM, whereas PPME 
was present at 100/zg/ml. All 
assays were performed in triplicate. Specific binding of [~25I]GMP- 
140 is expressed as a percentage of  binding in the absence of added 
carbohydrate (mean  +  SD, n  =  3). 
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to neutrophils.  Fixed neutrophils were treated with trypsin,  DIP- 
trypsin,  elastase,  or DIP-elastase  as described  in Materials  and 
Methods. Cells were incubated with [~25I]GMP-140 (0.1-0.3 riM) in 
the presence or absence of 100-fold excess unlabeled GMP-140 for 
1 h at 4°C. Bound and free GMP-140 were separated as described 
in Materials and Methods. All assays were performed in quadrupli- 
cate. Specific binding of [125I]GMP-140 is expressed as a percent- 
age of binding to sham-treated controls  (mean  +  SD, n  =  3). 
was due to either endogenous neutrophil proteases or pro- 
tease contamination in the neuraminidase preparations, neu- 
trophils were treated with DFP before fixation to inactivate 
endogenous serine proteases, and the neuraminidase incuba- 
tions were performed in the presence of 10 mg/ml HSA as 
well  as  several protease inhibitors.  The  specificity of the 
neuraminidase effect was further demonstrated by the ability 
of a  competitive neuraminidase inhibitor,  Neu2en5Ac (34, 
35),  to  prevent  the  neuraminidase-induced  reduction  in 
GMP-140 binding  to  neutrophils  (Fig.  6).  Neu2en5Ac  in- 
hibited the effect of neuraminidase in a dose-dependent man- 
ner with an IC50 of 2.5  mM (data not shown).  These data 
suggest that the neutrophil receptor for GMP-140 contains 
sialic acid residues that are essential for function.  Neutro- 
phils contain both o~2-3- and o~2-6-1inked sialic acids,  but 
ot2-8 linkages have not been detected (11, 12, 50). Partial loss 
Table II.  Effect of Anti-Le  • mAb or Neoglycoproteins on 
[~2~I]GMP-140 Binding to Neutrophils 
Final 
Agent added  concentration  % Control* 
Antibody¢ 
82H5  400 #g/ml  112 
Neoglycoprotein~ 
Lex-BSA  6.5  #M  96 
Sialyl-Lex-BSA  6.5  /~M  92 
* Bound and free [~25I]GMP-140 were separated as described in Materials and 
Methods.  Specific binding of [~251]GMP-140 is expressed as a percentage of 
sham-treated controls.  All assays were performed  in duplicate and the result 
shown is the mean of two independent experiments. 
Neutrophils (4  x  106/ml) were preincubated with mAb for 15 min at 4°C. 
A 250-#1 aliquot (106 cells) was then transferred  to 250 #1 of HBSS/HSA/ 
Ca  containing  0.1-0.2  nM  [~25I]GMP-140 in  the  presence  or  absence  of 
>t00-fold molar excess of unlabeled GMP-140. 
§ [~25I]GMP-140 (0.1-0.2 nM) in the presence or absence of >loo-fold excess 
of unlabeled GMP-140  was preincubated  with neoglycoproteins  at the indi- 
cated concentration for 10 rain at 4°C before addition of neutrophils. 
Figure  7.  Effect  of neuraminidase  treatment  on  [~25I]GMP-140 
binding  to neutrophils.  Fixed  neutrophils  were treated  with 0.2 
U/ml of either V. cholerae (VC) or Newcastle disease virus (NDV) 
neuraminldase as described in Methods, either in the presence or 
absence of 20 mM Neu2en5Ac. Cells were then  incubated with 
[125I]GMP-140 (0.1-0.3 riM) in the presence or absence of 100-fold 
excess unlabeled GMP-140 for 30 min at 4°C. For cells treated with 
NDV neuraminidase,  1 mM Neu2en5Ac was also included during 
the binding assay. Bound and free GMP-140 were separated as de- 
scribed in Materials and Methods.  All assays were performed  in 
quadruplicate.  Specific binding of [125I]GMP-140 is expressed as 
a percentage of binding to sham-treated controls  (mean  +  SD). 
of GMP-140 binding after treatment with NDV neuramini- 
dase implies that at least some of the sialic acid linkages in 
the receptor are of the tx2-3 type. The greater inhibition ob- 
served using the  V. cholerae enzyme may mean that oe2-6 
linkages  are also  required  for receptor function.  Alterna- 
tively,  the  essential  linkages  may all  be c~2-3 but  are  not 
equally accessible to hydrolysis by the NDV enzyme, which 
is part of an intact virus. Finally, substitutions on the sialic 
acids (30,  43) may have impeded the efficient action of the 
neuraminidases (58). 
Myeloid cells, in contrast to erythroid and lymphoid cells, 
are rich  in  fucosylated polylactosaminoglycans which  can 
terminate in c~2-3- or tx2-6-1inked  sialic acids (reviewed in 
reference 10).  These structures are present on both neutro- 
phil glycoproteins and glycolipids (11, 12,  50).  To examine 
the possible role of these glycans in GMP-140 recognition, 
we treated cells with endo-/3-galactosidase, which hydrolyzes 
the/31-4 linkage between galactose and N-acetylglucosamine 
(Gal/31-4GIcNAc) in unbranched polylactosaminyl side chains 
of glycoproteins (44, 45).  Pretreatment of fixed neutrophils 
with up to 0.2 U/ml of E. freundii endo-/3-galactosidase for 
30 min, or up to 0.4 U/ml ofB. fragilis endo-/3-galactosidase 
for 60 min, had no effect on specific binding of GMP-140 
(data not  shown).  The lack of effect of these enzymes on 
binding suggests that the GMP-140 recognition structure is 
not on a polylactosamine side chain. Alternatively, the rele- 
vant side chain(s) may not be susceptible to enzymatic hy- 
drolysis under these conditions. Resistance to hydrolysis by 
endo-/3-galactosidase may occur if the glycans are not acces- 
sible to the enzyme on the surface of an intact neutrophil. 
Highly  fucosylated  and/or  branched  polylactosaminogly- 
cans may also be resistant to hydrolysis by this enzyme (44, 
45); however, branched polylactosaminoglycans are not pres- 
ent in neutrophils (10). 
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and Neu5Aca2-3Galf31-4(Fucod-3)GlcNAc (sialyl-Le  ~) are 
present as nonreducing termini on polylactosaminoglycans 
isolated from human neutrophil glycopeptides (11, 50). Le  x, 
which is also present on neutrophil glycolipids (12), is recog- 
nized by a  number of mAbs  specific for neutrophils and 
monocytes (18, 47, 49, 54, 57). Our neuraminidase and pro- 
tease studies indicate that Le  x per se cannot constitute the 
recognition structure for GMP-140. In support of  this conclu- 
sion, we found that preincubation of neutrophils with 400 
#g/ml of the anti-Le  x mAb 82H5 had no effect on binding 
of [J25I]GMP-140 (Table II).  To  further examine  whether 
Le  x or sialyl-Le  x are involved in GMP-140 recognition, we 
measured binding  of [t25I]GMP-140  to  neutrophils  in  the 
presence of the multivalent neoglycoproteins Lex-BSA and 
sialyl-Lex-BSA.  Neither conjugate  diminished  [~2~I]GMP- 
140  binding  (Table II).  Under  these  conditions  the  con- 
jugates were in >10~-fold molar excess over [~25I]GMP-140. 
To examine whether the Lex-BSA was functional, we used 
flow cytometry to test its ability to inhibit binding of two 
anti-Le  x mAbs to neutrophils.  Under conditions in which 
the conjugate was in -~-350-fold molar excess over antibody 
(see Materials and Methods), Le~-BSA inhibited 82H5 and 
anti-Leu-Ml binding by 75 and 95 %, respectively, whereas 
sialyl-Lex-BSA had no effect (data not shown).  These re- 
suits confirm that the Le~-BSA conjugate is functional, since 
it inhibited binding of both anti-Le  x antibodies at concentra- 
tions well below those which had no effect on [~25I]GMP-140 
binding.  The data also confirm the specificity of the two 
mAbs, since Le~-BSA, but not sialyl-Le  x, inhibited antibody 
binding.  A  similar  analysis  of the  functional  efficacy of 
sialyl-Lex-BSA was not performed because an antibody to 
sialyl-Le  ~ was  not available.  Nevertheless,  the concentra- 
tions of both neoglycoproteins used in these studies were 
well in excess of  those capable of blocking cell-cell adhesion 
and receptor-ligand interactions in other systems (8,  42). 
These results provide substantial evidence that the Le  ~  struc- 
ture is not involved in GMP-140 binding. They also suggest 
that  sialyl-Le  x is  either  not  a  recognition  structure  for 
GMP-140 or that other carbohydrate and/or protein compo- 
nents  are  required  to  enhance  its  affinity and/or  avidity 
for GMP-140. 
Discussion 
Our findings indicate that GMP-140 binds rapidly, reversibly, 
and saturably to receptors on human neutrophils.  The K~ 
and number of these receptors could not be determined pre- 
cisely because of the heterogeneous sedimentation behavior 
of GMP-140 at detergent concentrations below the CMC for 
Lubrol PX. However, it is clear that neither the density nor 
the apparent affinity of  the receptors is altered by stimulation 
of cells with the pharmacological agonist PMA. The recep- 
tors still interact with GMP-140 when neutrophils are chilled 
to 4°C or fixed with paraformaldehyde (this study and 13). 
These properties contrast with those of the/32 leukocyte inte- 
grins, where at least some adhesive functions require meta- 
bolically active cells and/or cellular activation (2, 25, 31, 39, 
41,  59). 
Purified GMP-140 binds to monocytes as well as neutro- 
phils,  but not to lymphocytes or erythrocytes, supporting 
previous observations that GMP-140 mediates adhesion of 
stimulated platelets only to neutrophils and monocytes (27). 
Furthermore, neither quiescent nor activated platelets bind 
GMP-140.  The observation that thrombin-stimulated plate- 
lets, which express GMP-140 on their surface, do not bind 
[~25I]GMP-140, suggests that homotypic interactions do not 
occur between GMP-140 molecules on opposing cells. 
Another selectin, the Mel 14/Leu 8 antigen, is present on 
neutrophils and monocytes (23, 56) and has been suggested 
to be a candidate receptor for GMP-140. However, two lines 
of evidence indicate that the Leu 8 antigen is not a GMP-140 
receptor. First, it is expressed on 70% of peripheral blood 
lymphocytes (23,  56),  which do not bind GMP-140 (this 
study) or rosette-activated platelets (27). Second, it is rap- 
idly shed from the neutrophil (22, 24) and lymphocyte (21, 
56) surface as a consequence of cellular activation. In con- 
trast, stimulation of neutrophils with PMA does not alter the 
number or apparent affinity of receptors for GMP-140, al- 
though it does down-regulate surface expression of the Leu 
8 antigen. 
Neuraminidase pretreatment of neutrophils markedly di- 
minishes GMP-140 binding, a clear parallel to the ability of 
neuraminidase pretreatment of HEVs of peripheral lymph 
nodes to prevent Mel 14/Leu 8 antigen-dependent lympho- 
cyte adhesion (40). However, the effects of soluble carbohy- 
drates on GMP-140 binding are different from those observed 
for lymphocyte binding to peripheral lymph node HEVs. 
This suggests that the carbohydrate structures on the GMP- 
140 receptor are distinct from those on the receptors for the 
Mel  14/Leu 8 antigen.  The effect of neuraminidases indi- 
cates that the  molecules recognized by GMP-140 contain 
u2-3- and perhaps u2-6-1inked sialic acids essential for func- 
tion. It is also possible that the critical sialic acid residues 
carry substitutions (43, 58) that may be required for GMP- 
140 recognition. Our findings are consistent with the hypoth- 
esis that the lectin-like domain of GMP-140 binds to oligo- 
saccharides containing terminal sialic acids.  A  less likely 
possibility is that removal of sialic acids affects the confor- 
mation of other functionally important regions of the  re- 
ceptor. 
The loss of GMP-140 binding after protease treatment of 
neutrophils  indicates  that  the  receptor  is  a  glycoprotein 
rather than a glycolipid. This conclusion is strengthened by 
observations  that  accessibility  of glycolipids to  antibody 
binding is actually increased after protease treatment of in- 
tact cells (51, 62). Binding of GMP-140 to its receptor may 
be due to both protein-protein and protein-carbohydrate in- 
teractions. Alternatively, GMP-140 may bind strictly to an 
oligosaccharide, but the protein core of the receptor may 
present the oligosaccharide in the configuration optimal for 
binding. 
A possible oligosaccharide target for GMP-140 binding is 
a polylactosaminoglycan modified by terminal sialic acid. 
Our data indicate that Le  x and sialyl-Le  x, which are termi- 
nal  structures on neutrophil polylactosaminoglycans (34), 
are not sufficient to mediate GMP-140 binding. However, we 
cannot exclude the possibility that one of these glycans, par- 
ticularly sialyl-Le  ~, constitutes part of a more complex rec- 
ognition structure for GMP-140.  If so,  it may be part of a 
polyfucosylated lactosaminoglycan that is  resistant  to hy- 
drolysis by endo-/~-galactosidase. 
When platelets and endothelial ceils are stimulated with 
receptor-mediated agonists such as thrombin, GMP-140 is 
redistributed within minutes from the membranes of secre- 
tory storage granules to the plasma membrane (3,  16,  32, 
Moore et al. Binding of GMP-140 to Neutrophils  497 52).  The current  study  suggests that,  once GMP-140  is ex- 
pressed on the cell surface, it will bind rapidly and reversibly 
to its receptor on leukocytes. These properties should allow 
it to mediate rapid,  regulated targeting  of neutrophils and 
monocytes to sites of acute inflammation or hemorrhage. 
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